Experience

Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie

June 30, 2025

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Ken Rollins
Partner in Charge – San Diego, San Diego
Edmond Lay
Partner, San Diego
Charity Williams
Partner, San Diego
Lindsey O'Crump
Associate, Washington, DC
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Christopher Kimball
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
W. Chad Shear
Partner, San Diego
Jeffrey J. Tolin
Partner, New York
Stacey A. Bradford
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Rachel Thorn
Of counsel, New York
Alexandria Ashour
Associate, San Diego
Navya Dasari
Associate, New York
Joshua Elefant
Associate, Palo Alto
Tony P. Guan
Associate, Santa Monica
Michelle Hunt
Associate
Emily Mok
Associate, Reston
Jonathan Perez-Reyzin
Associate, San Diego
Breanna Qin
Associate, Palo Alto
Christopher Suhler
Associate, Colorado
Novak Topalovic
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Rubin Waranch
Associate, Colorado
Yuhan Wu
Associate, Palo Alto
Joanna Zhang
Associate, San Diego
Jessica Wade
Paralegal Specialist, San Diego

Related Practices & Industries

Beta Bionics Announces Upsized $234.6 Million IPO, Concurrent $17 Million Private Placement

January 31, 2025

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Read more

Related contacts

Carlos Ramirez
Partner, San Diego
Mark Weeks
Partner, Palo Alto
Charlie Kim
Partner, San Diego
Christine S. Kim
Associate, San Diego
Heidi E. Wang
Associate, San Diego
Alexis Guillermo Buz
Associate, San Diego
Joanna Zhang
Associate, San Diego
Jessica Wade
Paralegal Specialist, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Sarah Miller
Associate, New York
Jessica Koffel
Special Counsel, Brussels
Thomas Welk
Senior Counsel, San Diego
Dani Nazemian
Special Counsel, San Diego
Ross Eberly
Partner, Santa Monica
Joanna Liebes Hubberts
Partner, San Diego
Alexandra Paterson
Associate, London
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Stephanie Gentile
Partner, New York
Calvin Lee
Associate, New York
Michael Egan
Partner, Washington, DC
Tania Soris
Associate, New York
Rebecca Ross
Special Counsel, Washington, DC
Francis Wheeler
Senior Counsel, Colorado

Related Practices & Industries

Wugen Closes Oversubscribed $172 Million Series B Financing

December 12, 2022

Cooley represented Wugen, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies, on its oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management. Partner Tom Coll led the Cooley team.

Related contacts

Heidi E. Wang
Associate, San Diego
Edmond Lay
Partner, San Diego
Tom Coll
Partner, San Diego

Related Practices & Industries

Bright Peak Therapeutics Closes $107 Million Series B Financing

December 12, 2022

Cooley represented Bright Peak Therapeutics, a biotechnology company developing next-generation immunotherapies to treat cancer and autoimmune disease, in its $107 million Series B financing led by RA Capital. Partner Tom Coll led the Cooley team.

Related contacts

Edmond Lay
Partner, San Diego
Heidi E. Wang
Associate, San Diego
Tom Coll
Partner, San Diego

Related Practices & Industries

Poseida Therapeutics – $80.5 Million Follow-on Offering

September 7, 2022

Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.

Related contacts

Tom Coll
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Partner, San Diego
Edmond Lay
Partner, San Diego
Heidi E. Wang
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

View more

Admissions and credentials

California